AstraZeneca to acquire worldwide rights to Dizal's lung cancer drug Zegfrovy for $600 million
read at Endpoints ↗DealNeutral
AstraZeneca announced it will pay $600 million upfront to Dizal Pharmaceutical for the worldwide development and sales rights to the lung cancer drug Zegfrovy.
The agreement gives AstraZeneca full control over Zegfrovy's global commercialization, while Dizal, a company in which AstraZeneca holds a partial stake, retains a financial interest.
The deal was disclosed on July 14, 2026 and reflects AstraZeneca's strategy to expand its oncology portfolio through strategic acquisitions.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “AstraZeneca to take rights to Dizal's lung cancer pill Zegfrovy”
read at Endpoints ↗84 words · retrieved Jul 14
comments(0)
5-min edit window · permanent after that